Abimbola Williams
About Abimbola Williams
Abimbola Williams is the Manager of Health Economics at Boston Scientific, with extensive experience in health economics and policy, having worked in various roles at Terumo Medical Corporation, The Medicines Company, and Rutgers University, among others.
Title
Abimbola Williams currently holds the position of Manager, Health Economics at Boston Scientific. She has been in this role since 2020, based in Parsippany, NJ.
Previous Experience
Before joining Boston Scientific, Abimbola Williams amassed significant experience in various roles. She served as Market Research Analyst at Terumo Medical Corporation from 2017 to 2020 in Somerset, NJ. Prior to that, she was an HEOR Analyst-Value at The Medicines Company, a role she held for seven months in 2016-2017 in Parsippany, NJ. Her other positions have included Research Project Manager at Rutgers University (2015-2016), Consultant at UNDP in Lagos (2011-2012), and multiple roles at Johns Hopkins Bloomberg School of Public Health in 2011.
Education and Expertise
Abimbola Williams holds a PhD in Health Economics and Policy from Lancaster University. She also earned a Master of Science (MS) in Health Outcomes, Policy & Economics from Rutgers University in 2016. Additionally, she has a diploma in Public Health Policy & Management from Johns Hopkins Bloomberg School of Public Health and an MPH in Medical Demography from the University of Ibadan. Her educational journey began with a BSc in Microbiology from Ahmadu Bello University.
Professional Background
Abimbola Williams has a diverse professional background, including significant roles at the Center for the Right to Health as a Program Officer for 11 years and various positions within academic institutions and international organizations. Her multifaceted expertise spans health economics, market research, and public health policy.
Health Economic Research Initiatives
Abimbola Williams has independently led health economic and outcome research projects focused on cardiovascular disease. Her work includes developing a policy brief and value proposition framework for PCSK9 drugs, conducting epidemiological reviews of hyperlipidemia and atherosclerosis, and compiling ICD 9 and 10 codes for cardiovascular diseases and related CPT procedures.